Kiniksa Pharmaceuticals Analyst Ratings
Kiniksa Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/26/2023 | 64.27% | Goldman Sachs | $22 → $32 | Maintains | Buy |
| 03/09/2023 | 2.67% | JP Morgan | $19 → $20 | Maintains | Overweight |
| 12/29/2021 | 74.54% | B of A Securities | $37 → $34 | Maintains | Buy |
| 04/01/2020 | 28.34% | B of A Securities | → $25 | Initiates Coverage On | → Buy |
| 03/11/2020 | 23.2% | JP Morgan | $22 → $24 | Maintains | Overweight |
| 12/06/2019 | -7.6% | Goldman Sachs | $16 → $18 | Upgrades | Neutral → Buy |
| 08/14/2019 | 79.67% | JMP Securities | $44 → $35 | Maintains | Market Outperform |
| 03/11/2019 | 33.47% | Barclays | → $26 | Initiates Coverage On | → Overweight |
| 12/12/2018 | 69.4% | Wedbush | $31 → $33 | Reiterates | Outperform → Outperform |
| 09/17/2018 | 125.87% | JMP Securities | $33 → $44 | Maintains | Market Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/26/2023 | 64.27% | 高盛 | 22 美元 → 32 美元 | 維護 | 購買 |
| 03/09/2023 | 2.67% | 摩根大通 | 19 美元 → 20 美元 | 維護 | 超重 |
| 12/29/2021 | 74.54% | B of A 證券 | 37 美元 → 34 美元 | 維護 | 購買 |
| 2020 年 1 月 4 日 | 28.34% | B of A 證券 | → 25 美元 | 啓動覆蓋開啓 | → 購買 |
| 03/11/2020 | 23.2% | 摩根大通 | 22 美元 → 24 美元 | 維護 | 超重 |
| 2019 年 6 月 12 日 | -7.6% | 高盛 | 16 美元 → 18 美元 | 升級 | 中性 → 買入 |
| 08/14/2019 | 79.67% | JMP 證券 | 44 美元 → 35 美元 | 維護 | 市場跑贏大盤 |
| 2019 年 11 月 3 日 | 33.47% | 巴克萊 | → 26 美元 | 啓動覆蓋開啓 | → 超重 |
| 2018 年 12 月 12 日 | 69.4% | Wedbush | 31 美元 → 33 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 09/17/2018 | 125.87% | JMP 證券 | 33 美元 → 44 美元 | 維護 | 市場跑贏大盤 |
What is the target price for Kiniksa Pharmaceuticals (KNSA)?
Kiniksa Pharmicals（KNSA）的目標價格是多少？
The latest price target for Kiniksa Pharmaceuticals (NASDAQ: KNSA) was reported by Goldman Sachs on July 26, 2023. The analyst firm set a price target for $32.00 expecting KNSA to rise to within 12 months (a possible 64.27% upside). 2 analyst firms have reported ratings in the last year.
高盛於2023年7月26日公佈了Kiniksa Pharmicals（納斯達克股票代碼：KNSA）的最新目標股價。這家分析公司將目標股價定爲32.00美元，預計KNSA將在12個月內升至12個月內（可能上漲64.27％）。去年有2家分析公司公佈了評級。
What is the most recent analyst rating for Kiniksa Pharmaceuticals (KNSA)?
Kiniksa Pharmicals（KNSA）的最新分析師評級是多少？
The latest analyst rating for Kiniksa Pharmaceuticals (NASDAQ: KNSA) was provided by Goldman Sachs, and Kiniksa Pharmaceuticals maintained their buy rating.
Kiniksa Pharmicals（納斯達克股票代碼：KNSA）的最新分析師評級由高盛提供，Kiniksa Pharmicals維持買入評級。
When is the next analyst rating going to be posted or updated for Kiniksa Pharmaceuticals (KNSA)?
Kiniksa Pharmicals（KNSA）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiniksa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiniksa Pharmaceuticals was filed on July 26, 2023 so you should expect the next rating to be made available sometime around July 26, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Kiniksa Pharmicals的高管和客戶交談以及聽取財報電話會議）後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Kiniksa Pharmicals的最新評級是在2023年7月26日提交的，因此您應該預計下一個評級將在2024年7月26日左右公佈。
Is the Analyst Rating Kiniksa Pharmaceuticals (KNSA) correct?
分析師對Kiniksa Pharmicals（KNSA）的評級正確嗎？
While ratings are subjective and will change, the latest Kiniksa Pharmaceuticals (KNSA) rating was a maintained with a price target of $22.00 to $32.00. The current price Kiniksa Pharmaceuticals (KNSA) is trading at is $19.48, which is out of the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Kiniksa Pharmicals（KNSA）評級維持不變，目標股價爲22.00美元至32.00美元。Kiniksa Pharmicals（KNSA）目前的交易價格爲19.48美元，超出了分析師的預測區間。